<DOC>
	<DOCNO>NCT01482143</DOCNO>
	<brief_summary>The aim study characterize pharmacokinetics safety/tolerability AFQ056 child Fragile X Syndrome ( FXS )</brief_summary>
	<brief_title>Clinical Study Assess Pharmacokinetics , Safety Tolerability Single Multiple Oral Doses AFQ056 Children With Fragile X Syndrome ( FXS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Genetically confirm diagnosis FXS At Screening first baseline , vital sign , body weight body mass index ( BMI ) must agespecific within normal range . Use investigational drug within 30 day 5 halflives ( whichever longer ) investigational drug prior screen end study visit . History hypersensitivity AFQ056 mGluR antagonist . Female patient confirm suspect sexually active . History presence clinically significant disease major system organ class , within past 2 year prior screen include limited psychiatric , neurological , cardiovascular , endocrine , metabolic , renal , gastrointestinal disorder ( except typical feature FXS ) . Smokers . Loss â‰¥10 % total blood volume within 8 week ( less require age group and/or local regulation ) prior dose longer required age group and/or local regulation . Significant illness completely resolve least four week prior first baseline visit . Any abnormal laboratory value screen first baseline opinion investigator clinically significant may jeopardize safety study subject . Use ( use within least 5 half life dose ) concomitant medication strong/moderate inhibitor inducer CYP1A1/2 , CYP2C9/19 CYP3A4 History presence Hepatitis B/C HIV screen</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Fragile X Syndrome</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety tolerability</keyword>
</DOC>